251 related articles for article (PubMed ID: 9396012)
1. Gene therapy for Parkinson's disease.
Horellou P; Mallet J
Mol Neurobiol; 1997 Oct; 15(2):241-56. PubMed ID: 9396012
[TBL] [Abstract][Full Text] [Related]
2. In vivo adenovirus-mediated gene transfer for Parkinson's disease.
Horellou P; Bilang-Bleuel A; Mallet J
Neurobiol Dis; 1997; 4(3-4):280-7. PubMed ID: 9361305
[TBL] [Abstract][Full Text] [Related]
3. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease.
Cunningham LA; Su C
Exp Neurol; 2002 Apr; 174(2):230-42. PubMed ID: 11922664
[TBL] [Abstract][Full Text] [Related]
4. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.
Björklund A; Kirik D; Rosenblad C; Georgievska B; Lundberg C; Mandel RJ
Brain Res; 2000 Dec; 886(1-2):82-98. PubMed ID: 11119690
[TBL] [Abstract][Full Text] [Related]
5. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease.
Mandel RJ; Snyder RO; Leff SE
Exp Neurol; 1999 Nov; 160(1):205-14. PubMed ID: 10630205
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-mediated gene transfer to the central nervous system for Parkinson's disease.
Horellou P; Sabaté O; Buc-Caron MH; Mallet J
Exp Neurol; 1997 Mar; 144(1):131-8. PubMed ID: 9126162
[TBL] [Abstract][Full Text] [Related]
7. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF.
Bensadoun JC; Déglon N; Tseng JL; Ridet JL; Zurn AD; Aebischer P
Exp Neurol; 2000 Jul; 164(1):15-24. PubMed ID: 10877911
[TBL] [Abstract][Full Text] [Related]
8. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
[TBL] [Abstract][Full Text] [Related]
9. Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery.
Drinkut A; Tereshchenko Y; Schulz JB; Bähr M; Kügler S
Mol Ther; 2012 Mar; 20(3):534-43. PubMed ID: 22086235
[TBL] [Abstract][Full Text] [Related]
10. The generation of dopaminergic neurons by human neural stem cells is enhanced by Bcl-XL, both in vitro and in vivo.
Liste I; García-García E; Martínez-Serrano A
J Neurosci; 2004 Dec; 24(48):10786-95. PubMed ID: 15574729
[TBL] [Abstract][Full Text] [Related]
11. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease.
Eslamboli A; Georgievska B; Ridley RM; Baker HF; Muzyczka N; Burger C; Mandel RJ; Annett L; Kirik D
J Neurosci; 2005 Jan; 25(4):769-77. PubMed ID: 15673656
[TBL] [Abstract][Full Text] [Related]
12. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
[TBL] [Abstract][Full Text] [Related]
13. Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Eberhardt O; Coelln RV; Kugler S; Lindenau J; Rathke-Hartlieb S; Gerhardt E; Haid S; Isenmann S; Gravel C; Srinivasan A; Bahr M; Weller M; Dichgans J; Schulz JB
J Neurosci; 2000 Dec; 20(24):9126-34. PubMed ID: 11124990
[TBL] [Abstract][Full Text] [Related]
14. Biomedicine. Combating Parkinson's disease--step three.
Olson L
Science; 2000 Oct; 290(5492):721-4. PubMed ID: 11184202
[TBL] [Abstract][Full Text] [Related]
15. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain.
Kaplitt MG; Leone P; Samulski RJ; Xiao X; Pfaff DW; O'Malley KL; During MJ
Nat Genet; 1994 Oct; 8(2):148-54. PubMed ID: 7842013
[TBL] [Abstract][Full Text] [Related]
16. Viral vectors in the treatment of Parkinson's disease.
Latchman DS; Coffin RS
Mov Disord; 2000 Jan; 15(1):9-17. PubMed ID: 10634236
[TBL] [Abstract][Full Text] [Related]
17. Dopaminergic neurons protected from degeneration by GDNF gene therapy.
Choi-Lundberg DL; Lin Q; Chang YN; Chiang YL; Hay CM; Mohajeri H; Davidson BL; Bohn MC
Science; 1997 Feb; 275(5301):838-41. PubMed ID: 9012352
[TBL] [Abstract][Full Text] [Related]
18. Distinct efficacy of pre-differentiated versus intact fetal mesencephalon-derived human neural progenitor cells in alleviating rat model of Parkinson's disease.
Wang X; Lu Y; Zhang H; Wang K; He Q; Wang Y; Liu X; Li L; Wang X
Int J Dev Neurosci; 2004 Jun; 22(4):175-83. PubMed ID: 15245752
[TBL] [Abstract][Full Text] [Related]
19. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease.
Shen Y; Muramatsu SI; Ikeguchi K; Fujimoto KI; Fan DS; Ogawa M; Mizukami H; Urabe M; Kume A; Nagatsu I; Urano F; Suzuki T; Ichinose H; Nagatsu T; Monahan J; Nakano I; Ozawa K
Hum Gene Ther; 2000 Jul; 11(11):1509-19. PubMed ID: 10945765
[TBL] [Abstract][Full Text] [Related]
20. [Present status and future prospects for gene therapy in Parkinson's disease].
Muramatsu S
Nihon Naika Gakkai Zasshi; 2003 Aug; 92(8):1461-6. PubMed ID: 13677895
[No Abstract] [Full Text] [Related]
[Next] [New Search]
